Indianapolis-based Indiana University Health has become the first health system in the U.S. to administer Pixclara, a newly FDA-approved brain cancer imaging drug.
The drug is approved for use in adults and children with suspected recurrent glioma, according to an Oct. 6 news release from IU Health.
Pixclara helps physicians determine whether changes seen on imaging represent cancer recurrence or treatment effects, the release said.
The milestone is part of a broader push into theranostics at IU Health, which launched a Theranostics Center of Excellence in August, backed in part by a $20 million philanthropic gift.
At the Becker's Perioperative Summit, taking place September 14–15 in Chicago, perioperative leaders and healthcare executives will focus on improving operating room efficiency, enhancing patient safety, optimizing staffing and driving innovation across surgical services. Apply for complimentary registration now.
